Abstract:Background: Head and neck squamous cell carcinoma (HNSCC) is a common malignancy that often develops unnoticed. Typically, these tumors are identified at advanced stages, resulting in a relatively low chance of successful treatment. Anoikis serves as a natural defense against the spread of tumor cells, meaning circumventing anoikis can effectively inhibit tumor metastasis. Nonetheless, studies focusing on anoikis in the context of HNSCC remain scarce. Methods: Anoikis-related genes (ARGs) were identified by using the GeneCards and Harmonizome databases. Expression data of these genes and relevant clinical features were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. A LASSO regression and a prognostic risk score model were developed to determine their prognostic significance. The analysis included the use of the CIBERSORT algorithm to quantify immune and stromal cell presence. Furthermore, in vitro and in vivo, we confirmed the expression and functional roles of proteins and mRNA of genes independently predictive of prognosis. Results: The study identified eight genes linked to prognosis (ANXA5, BAK1, CDKN2A, PPARG, CCR7, MAPK11, CRYAB, CRYBA1) and developed a prognostic model that effectively forecasts the survival outcomes for patients with HNSCC. A higher survival likelihood is associated with lower risk scores. In addition, a significant relationship was found between immune and risk score, and ANXA5 deletion promoted the killing of HNSCC cells by activated T cells. During the screening process, 65 different chemotherapeutic drugs were found to have significant differences in IC50 values when comparing high- and low-risk categories. ANXA5 emerged as a gene with independent prognostic significance, exhibiting notably elevated protein and mRNA levels in HNSCC tissue compared to non-tumorous tissue. The suppression of ANXA5 gene activity resulted in a substantial decrease in both the growth and mobility of HNSCC cells. Animal model experiments demonstrated that inhibiting ANXA5 suppressed HNSCC growth and migration in vivo. Conclusion: Through bioinformatics, a prognostic risk model of high precision was developed, offering valuable insights into the survival rates and immune responses in patients with HNSCC. ANXA5 is highlighted as a significant prognostic factor among the identified genes, indicating its promise as a potential therapeutic target for those with HNSCC.

ANXA1: An Important Independent Prognostic Factor and Molecular Target in Glioma

ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression

Correlation of Expression Levels of ANXA2, PGAM1, and CALR with Glioma Grade and Prognosis.

Potential regulatory mechanism of TNF-α/TNFR1/ANXA1 in glioma cells and its role in glioma cell proliferation

SYST-16 ANXA5 PROMOTES GLIOMA PROGRESSION THROUGH THE FAK/PI3K/AKT PATHWAY

Overexpression of Annexin A2 Promotes Proliferation by Forming a Glypican 1/C-Myc Positive Feedback Loop: Prognostic Significance in Human Glioma

Knockdown of Annexin-A1 Inhibits Growth, Migration and Invasion of Glioma Cells by Suppressing the PI3K/Akt Signaling Pathway

Expression of TXLNA in brain gliomas and its clinical significance: a bioinformatics analysis

ANXA5 predicts prognosis and immune response and mediates proliferation and migration in head and neck squamous cell carcinoma

Annexin‐1 is an oncogene in glioblastoma and causes tumour immune escape through the indirect upregulation of interleukin‐8

Integrative Analysis Reveals the Potential Prognostic Roles and Immunological Values of Unc-5 Netrin Receptor A (UNC5A) in Glioma

SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma

Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment

ANTXR1 Facilitates Tumor Growth in Glioma Via Deactivating MAPK Signaling Pathway

Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients

Depleting ANTXR1 suppresses glioma growth via deactivating PI3K/AKT pathway

Correlation Study of Annexin A2 and Prognosis of Glioblastoma

Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway

Pseudogenes of Annexin A2, Novel Prognosis Biomarkers for Diffuse Gliomas

CHRNA9 As a New Prognostic Marker and Potential Therapeutic Target in Glioma.

A Bioinformatics-Based Analysis of an Anoikis-Related Gene Signature Predicts the Prognosis of Patients with Low-Grade Gliomas